Form 4: Eugene A. Woods Increases JNJ Deferred Share Holdings

Johnson & Johnson Director Eugene A. Woods acquired 161.089 deferred share units as part of the company's director compensation plan.

Summary

• Director Eugene A. Woods acquired 161.089 Deferred Share Units (DSUs) on June 9, 2026.
• The acquisition was made under the Issuer's Amended and Restated Deferred Fee Plan for Directors.
• The transaction price was $232.79 per unit.
• Following this transaction, the reporting person holds a total of 6,411.959 DSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Demonstrates continued alignment of director interests with long-term shareholder value through equity-linked compensation.

Negatives

• None identified; this is a routine compensation-related transaction.

Risks

• Value of deferred share units is subject to the market performance of Johnson & Johnson common stock.

Future Outlook

The DSUs will be settled in cash upon the termination of the reporting person's directorship, based on the fair market value of common stock at that time.

Industry Context

StockSavvy.ai notes that routine director equity acquisitions via deferred fee plans are standard corporate governance practices in large-cap pharmaceutical companies, signaling confidence in long-term stability.

Comparison to Industry Standards

• The use of deferred fee plans for directors is consistent with compensation structures at peer companies like Pfizer, Merck, and Eli Lilly.
• The transaction follows standard SEC reporting requirements for director compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation transaction.

Next Steps

• No specific future actions required by the reporting person other than continued service as a director.

Key Dates

Keywords

Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, Form 4